Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S149-S155

  Arida, A ^a   Sfikakis, Petros P ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Anti TNF agents; Beh et's disease; Biological treatment; Cytokines; IL 1; IL 17; IL 2; IL 6

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CANAKINUMAB; COLCHICINE; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; GEVOKIZUMAB; INFLIXIMAB; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SECUKINUMAB; TOCILIZUMAB; USTEKINUMAB; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

BEHCET DISEASE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME;

BEHCET SYNDROME; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907535458     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. INTERNATIONAL STUDY GROUP FOR BEH-çET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
2. HATEMI G, YAZICI Y, YAZICI H: Behçet's syndrome. Rheum Dis Clin North Am 2013; 39: 245-61.
3. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al.: The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
4. HATEMI G, SILMAN A, BANG D et al.: Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009; 68: 1528-34.
5. HATEMI G, SILMAN A, BANG D et al.: EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
6. SFIKAKIS PP, MARKOMICHELAKIS N, ALPSOY E et al.: Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007; 46: 736-41.
7. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP: Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70.
8. OZGULER Y, HATEMI G, YAZICI H: Management of Behçet's syndrome. Curr Opin Rheumatol 2014; 26: 285-91.
9. BUGGAGE RR, LEVY-CLARKE G, SEN HN et al.: A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 2007; 15: 63-70.
10. DICK AD, TUGAL-TUTKUN I, FOSTER S et al.: Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120: 777-87.
11. BOTSIOS C, SFRISO P, FURLAN A, PUNZI L, DINARELLO CA: Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008; 149: 284-6.
12. BILGINER Y, AYAZ NA, OZEN S: Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 2010; 29: 209-10.
13. EMMI G, SILVESTRI E, CAMELI AM et al.: Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 2013; 31 (Suppl. 77): S152-3.
14. CANTARINI L, VITALE A, SCALINI P et al.: Anakinra treatment in drug-resistant Behçet's disease: a case series. Clin Rheumatol 2013 Dec 5 [Epub ahead of print].
15. CASO F, RIGANTE D, VITALE A, LUCHERINI OM, CANTARINI L: Efficacy of anakinra in refractory Behçet's disease sacroiliitis. Clin Exp Rheumatol 2014; 32 (Suppl. 84): S171.
16. UGURLU S, UCAR D, SEYAHI E, HATEMI G, YURDAKUL S: Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis 2012; 71: 1589-91.
17. VITALE A, RIGANTE D, CASO F et al.: Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. Dermatology 2014; 228: 211-4.
18. GüL A, TUGAL-TUTKUN I, DINARELLO CA et al.: Interleukin-1ß-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 2012; 71: 563-6.
19. HIRANO T, OHGURO N, HOHKI S et al.: A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22: 298-302.
20. SHAPIRO LS, FARRELL J, BORHANI HAG-HIGHI A: Tocilizumab treatment for neuro-Behçet's disease, the first report. Clin Neurol Neurosurg 2012; 114: 297-8.
21. URBANIAK P, HASLER P, KRETZSCHMAR S: Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S73-5.
22. DIAMANTOPOULOS AP, HATEMI G: Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: report of two cases. Rheumatology (Oxford) 2013; 52: 1923-4.
23. REDONDO-PACHóN MD, ENRíQUEZ R, SIRVENT AE et al.: Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behçet's disease. Ren Fail 2013; 35: 547-50.
24. CASO F, IACCARINO L, BETTIO S et al.: Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. Immunol Res 2013; 56: 390-7.
25. CANTARINI L, LOPALCO G, VITALE A et al.: Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. Clin Rheumatol 2014 Apr 15. [Epub ahead of print]
26. BAERVELDT EM, KAPPEN JH, THIO HB, van LAAR JA, van HAGEN PM, PRENS EP: Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 2013; 72: 626-7.
27. PINETON de CHAMBRUN M, WECHSLER B, GERI G, CACOUB P, SAADOUN D: New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2012; 11: 687-98.
28. DüZGüN N, AYAŞLIOĞLU E, TUTKAK H, AYDINTUĞ OT: Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease. Rheumatol Int 2005; 25: 1-5.
29. AKMAN-DEMIR G, TüZüN E, IçöZ S et al.: Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine. 2008; 44: 373-6.
30. McINNES IB, KAVANAUGH A, GOTTLIEB AB et al.; PSUMMIT 1 StuTUdy GroupUP: Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-9.
31. CHI W, ZHU X, YANG P et al.: Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49: 3058-64.
32. NWE SM, CHAMPLAIN AH, GORDON KB: Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol 2013; 9: 677-82.
33. LI B, YANG P, ZHOU H et al.: T-bet expression is upregulated in active Behçet's disease. Br J Ophthalmol 2003; 87: 1264-7.
34. HAO WJ, ZONG HT, CUI YS, ZHANG Y: The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis. Transplant Proc 2012; 44: 2955-60.
35. PFENDER N, MARTIN R: Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol 2014 Apr 24 [Epub ahead of print].
36. KöTTER I, HAMURYUDAN V, OZTüRK ZE, YAZICI H: Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 2010; 22: 278-83.
37. MELIKOGLU M, FRESKO I, MAT C et al.: Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.